Indian stocks: Visit www.stage2stocks.com →

Definium Therapeutics, Inc.

Stage 3 · Topping · week 5

As of Oct 22, 2026, Definium Therapeutics is in Stage 3, the topping phase, now in week 5 (since Sep 23, 2026). It closed at $36.00, 25.7% below its 52-week high and above its 200-day average, which is rising.

Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. More about the company

$36.00
+1.35% today
$4.8B · Mid cap
Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is DFTX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S2 18w
S3 16w
S2 65w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 6w → S3 3w → S4 9w → S1 5w → S2 18w → S3 16w → S4 7w → S1 12w → S2 5w → S3 4w → S4 7w → S1 4w → S2 65w → S3 4w current
Total tracked: 166 weeks across 14 stage runs.

DFTX among Biotechnology15th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…15DFTXStage 3 · wk 598−4.4%
vs 52W High
-25.7%
$10.68 lo$48.45 hi
25.7% below 52W high, weakening from peak
The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.
Stage Maturity
Week 5
1w13w26w
Week 5, early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
24.4%
200 DMA: $28.93 · rising
Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.
Rel Volume
0.93x
vs 50-day avg
Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-4.4%
3M
-16.6%
6M
+54.8%
YTD
+163.9%
1Y
+184.8%
Scan Membership
Breakout Watch
Latest: 2025-06-27
7 appearances in last 60 days. First seen: 2020-02-12.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S3
Wk 5 · Vol 0.93x
2026-10-21S3
Wk 5 · Vol 1.26x
2026-10-20S3
Wk 4 · Vol 0.77x
2026-10-19S3
Wk 4 · Vol 0.76x
2026-10-16S3
Wk 4 · Vol 0.85x
2026-10-15S3
Wk 4 · Vol 0.77x
2026-10-14S3
Wk 4 · Vol 0.77x
2026-10-13S3
Wk 3 · Vol 0.88x
2026-10-12S3
Wk 3 · Vol 0.84x
2026-10-09S3
Wk 3 · Vol 1.23x
2026-10-08S3
Wk 3 · Vol 0.94x
2026-10-07S3
Wk 3 · Vol 0.87x
Moving averages & range
50 DMA
$38.74
200 DMA
$28.93
52W High
$48.45
52W Low
$10.68
5D Low
$32.10
Resistance levels (recent highs)
20d High
$38.41
60d High
$46.18
120d High
$48.45
250d High
$48.45
Next resistance
+6.7%
to 20d High
ROE
-64.1%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 5.3

Definium Therapeutics: quick answers

What stage is Definium Therapeutics in?

As of Oct 22, 2026, Definium Therapeutics (DFTX) is in Stage 3, the topping phase. It entered Stage 3 on Sep 23, 2026 and is in week 5. What the four stages mean

Is Definium Therapeutics in an uptrend?

Its uptrend has stalled. Definium Therapeutics is in Stage 3, the topping phase that follows an advance. It trades 24.4% above its 200-day average, which is rising.

How far is Definium Therapeutics from its 52-week high?

Definium Therapeutics closed at $36.00 on Oct 22, 2026, 25.7% below its 52-week high of $48.45. Its 52-week low is $10.68.

How has Definium Therapeutics performed over the past year?

As of Oct 22, 2026, Definium Therapeutics is up 184.8% over the past year and up 163.9% so far in 2026.

Which sector and industry is Definium Therapeutics in?

Definium Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.